FDA Authorizes AstraZeneca’s Long-Acting Antibody To Prevent COVID-19

By Kelly Lienhard / December 8, 2021 at 7:23 PM
FDA on Wednesday (Dec. 8) authorized AstraZeneca’s long-acting antibody cocktail, Evusheld (tixagevimab co-packaged and administered with cilgavimab), the first treatment authorized to prevent COVID-19 infections in patients who are immunocompromised or unable to receive one of the authorized coronavirus vaccines. One dose of Evusheld, which is authorized for patients 12 years of age and older who weigh at least 40 kilograms (about 88 pounds), might offer pre-exposure prevention of COVID-19 for six months, FDA says. AstraZeneca is conducting studies to...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.